↓ Skip to main content
What is this page? Embed badge

Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas

Overview of attention for article published in Clinical Lymphoma, Myeloma & Leukemia, September 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
2 news outlets

Readers on

mendeley
31 Mendeley
So far, Altmetric has seen 4 news stories from 2 outlets.
This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.